Cephalon, Inc.

Teva Pharmaceuticals Australia Pty Ltd

Cephalon Australia Pty. Ltd.

Andrew James Pow

Anthony Gerard Doyle

Adam Clarke

Lynn Dorothy Poulton

George Kopsidas

Philip Anthony Jennings

Matthew Pollard

Debra Tamvakis

Bernadette Wai

Adam William Clarke

The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.

Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases

Antibodies against TL1a and uses thereof

The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R &#x3b2;2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R&#x3b2;1.

Anti-IL-12/IL-23 antibodies

Growing community of inventors

Pascoe Vale, Australia

Andrew James Pow